Pasireotide (Signifor)

FDA-approved product existsPeptideGH axis & hormones

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Pasireotide (Signifor)?

FDA-approved pasireotide is marketed as Signifor for specified adults with Cushing disease; a long-acting formulation has a separate label for specified uses.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelSIGNIFOR prescribing information for Cushing's disease
PopulationAdults covered by the approved SIGNIFOR indication
DoseInitial dose is 0.6 mg or 0.9 mg twice daily; the labeled range is 0.3-0.9 mg twice daily with response- and tolerability-based titration.
RouteSubcutaneous injection
FrequencyTwice daily
DurationLong-term use within the approved indication with label-directed monitoring
PreparationReady-to-use 0.3 mg/mL, 0.6 mg/mL, or 0.9 mg/mL single-dose ampule; no reconstitution.
Source: Dosage and Administration sections 2.1-2.3; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.